What type of medicine is Eltrombopag?

Eltrombopag (Eltrombopag) is an oral, small molecule, non-peptide thrombopoietin receptor agonist. The drug selectively binds to the thrombopoietin receptor transmembrane domain on the surface of platelets, megakaryocytes, and megakaryocyte precursor cells and acts by activating the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. Eltrombopag's main function is to promote platelet production and is suitable for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenic purpura (ITP), especially those who have poor response to corticosteroids, immunoglobulins, or splenectomy.

Eltrombopag was first approved by the US FDA in 2008 and has been approved for use in more than 100 countries around the world. In China, eltrombopag was approved in 2018, providing a new treatment option for ITP patients. This drug can not only quickly increase platelet count, but as an oral drug, it is easy to take, greatly improving patients' medication compliance.

However, special attention needs to be paid to hepatotoxicity when using eltrombopag. Because it may increase serum aminotransferase levels and bilirubin, liver chemistries must be measured before starting treatment and periodically during treatment. Particular caution should be exercised when administering to patients with impaired hepatic function.

In addition, the dosage adjustment of eltrombopag is also a key step in the treatment process. The starting dose is usually 50 mg per day. For Orientals or patients with moderate to severe hepatic impairment, the starting dose is adjusted to 25 mg per day and must be administered on an empty stomach. During the treatment process, the doctor will adjust the drug dosage according to the patient's platelet count and liver function to achieve the best therapeutic effect.

Overall, eltrombopag is an important drug for the treatment of chronic immune thrombocytopenic purpura. It helps patients increase platelet counts and reduce the risk of bleeding by promoting platelet production. However, during use, the patient's liver function and platelet count need to be closely monitored to ensure the safety and effectiveness of the treatment.